Sosei Group Corporation announces the appointment of Andrew Oakley as Chief Financial Officer (CFO) effective from February 1 2017. Mr Oakley will be based in Sosei’s Tokyo offices. Mr Oakley will succeed Mr Hidetoshi Torami who has resigned from Sosei for personal reasons.
Mr Oakley, a Cha ... more
Evotec AG announced it has entered into an integrated drug discovery collaboration on an ion channel target with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan.
Under the terms of the agreement, Evotec will apply its integrated drug discov ... more
The only facility in Europe solely dedicated to meglumine production
Merck announced the opening of a facility in Mollet des Vallès, Spain dedicated to the manufacture of meglumine, an FDA-approved excipient for pharmaceuticals and a component of medical imaging contrast media.The facility, validated by the FDA, is the only location in Europe that manufactur ... more
WILEX AG and Australian biopharmaceutical company Telix Pharmaceuticals Limited, announced that they have concluded a worldwide license agreement for the development and commercialization of the imaging agent REDECTANE®, a radiolabeled form of the monoclonal antibody Girentuximab. Girentuxi ... more
Evotec AG and MaRS Innovation announced the launch of Fibrocor Therapeutics LP, a Toronto-based company focused on developing first-in-class therapeutics targeting fibrotic diseases. The company was launched with CDN $ 2.8 m (approx. $ 2.1 m) financing, which includes cash from MaRS Innovat ... more
Grünenthal announced the introduction of its new women’s health products plant today. Grünenthal invested USD 14.5 million to build the 1,150 m 2 hormone plant, which is the company’s center of excellence for hormone production and the most modern in Latin America. The new facility will ini ... more
Merck is actively seeking more partnerships and collaborations
Merck announced two collaborations in the metropolitan area of San Francisco, California (USA). The company is now cooperating with Palantir Technologies Inc., Palo Alto, California, and with the Stanford Graduate School of Business (Stanford GSB), Stanford, California. In addition, Merck s ... more
OHSU research suggests an avenue for developing treatments for chronic pain that harness the medicinal properties of cannabis while minimizing the threat of addiction.
The study , conducted in a rodent model, provides additional rationale for the development of therapeutics using cannabinoi ... more
Bacterial cells have an added layer of protection, called the cell wall, that animal cells don't. Assembling this tough armor entails multiple steps, some of which are targeted by antibiotics like penicillin and vancomycin.
Yet one step in the process has remained a mystery because the mole ... more
The University of Illinois at Chicago College of Pharmacy has received a five-year, $1.25 million federal grant to continue its research into how bacteria that cause streptococcal infections can be manipulated.
By studying the chemical signals of bacteria, Michael Federle, associate profess ... more